https://scholars.lib.ntu.edu.tw/handle/123456789/582410
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Bieber, Thomas | en_US |
dc.contributor.author | Simpson, Eric L | en_US |
dc.contributor.author | Silverberg, Jonathan I | en_US |
dc.contributor.author | Thaçi, Diamant | en_US |
dc.contributor.author | Paul, Carle | en_US |
dc.contributor.author | Pink, Andrew E | en_US |
dc.contributor.author | Kataoka, Yoko | en_US |
dc.contributor.author | CHIA-YU CHU | en_US |
dc.contributor.author | DiBonaventura, Marco | en_US |
dc.contributor.author | Rojo, Ricardo | en_US |
dc.contributor.author | Antinew, Jeremias | en_US |
dc.contributor.author | Ionita, Ileana | en_US |
dc.contributor.author | Sinclair, Rodney | en_US |
dc.contributor.author | Forman, Seth | en_US |
dc.contributor.author | Zdybski, Jacek | en_US |
dc.contributor.author | Biswas, Pinaki | en_US |
dc.contributor.author | Malhotra, Bimal | en_US |
dc.contributor.author | Zhang, Fan | en_US |
dc.contributor.author | Valdez, Hernan | en_US |
dc.date.accessioned | 2021-09-07T08:35:09Z | - |
dc.date.available | 2021-09-07T08:35:09Z | - |
dc.date.issued | 2021 | - |
dc.identifier.issn | 00284793 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/582410 | - |
dc.description.abstract | The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | The New England journal of medicine | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | abrocitinib; dupilumab; placebo; abrocitinib; dupilumab; immunoglobulin A; interleukin 4 receptor alpha; Janus kinase 1; monoclonal antibody; placebo; protein kinase inhibitor; pyrimidine derivative; sulfonamide; adult; Article; atopic dermatitis; comparative effectiveness; controlled study; dose response; double blind procedure; drug dose comparison; drug safety; female; human; loading drug dose; major clinical study; male; nausea; phase 3 clinical trial; priority journal; prospective study; randomized controlled trial; skin pruritus; atopic dermatitis; blood; clinical trial; comparative study; multicenter study; oral drug administration; pruritus; severity of illness index; subcutaneous drug administration; Administration, Oral; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunoglobulin A; Injections, Subcutaneous; Interleukin-4 Receptor alpha Subunit; Janus Kinase 1; Male; Placebos; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Severity of Illness Index; Sulfonamides | - |
dc.title | Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1056/NEJMoa2019380 | - |
dc.identifier.pmid | 33761207 | - |
dc.identifier.scopus | 2-s2.0-85103370979 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85103370979 | - |
dc.relation.journalvolume | 384 | en_US |
dc.relation.journalissue | 12 | en_US |
dc.relation.pageend | 1112 | en_US |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
crisitem.author.dept | Dermatology | - |
crisitem.author.dept | Dermatology-NTUH | - |
crisitem.author.orcid | 0000-0002-9370-3279 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。